MedTrace Logo

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-05-30

No results posted yet for this study

Summary

The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101

Conditions

  • Healthy

Interventions

DRUG

ATX-101

ATX-101 single dose

Sponsors & Collaborators

  • Kythera Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dennis Swearingin, M.D. · MDS Pharma Services

  • Frederick Beddingfield, M.D. · Sponsor GmbH

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618709 on ClinicalTrials.gov